[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100287556":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":47,"collaborators":49,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":10,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"University of Wisconsin, Madison","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PMMTB",null,"This study of the PMMTB will include all patients \\>= 18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor.\n\nAll standard of care functions will be performed by standard procedures.",[13],"Other: PMMTB (Precision Medicine Molecular Tumor Board)",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"PMMTB (Precision Medicine Molecular Tumor Board)","PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.",[9],[20],{"name":21,"affiliation":5,"role":22},"Dustin Deming, MD","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Cancer Connect","CONTACT","8006228922","clinicaltrials@cancer.wisc.edu",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"University of Wisconsin Carbone Cancer Center","RECRUITING","Madison","Wisconsin","53792","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-89.40123,43.07305,{"lat":42,"lon":41},[45],{"name":25,"role":26,"phone":46,"phoneExt":10,"email":28},"800-622-8922",{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[50],{"name":51,"class":52},"National Cancer Institute (NCI)","NIH","100287556","uwccc-molecular-tumor-board-registry-100287556",false,"NCT03023202","UWCCC Molecular Tumor Board Registry","UWCCC Precision Medicine Molecular Tumor Board Registry","Inclusion Criteria:\n\n* Clinically suspected or histologically confirmed solid or hematological malignancy\n* Undergoing genetic testing of tumor\n* Ability to understand written informed consent document\n* Willingness to sign written informed consent document\n\nExclusion Criteria:\n\n* Pediatric patients (age\\\u003C18 years) will be excluded due to a lack of expertise on the molecular tumor committee","ALL","18 Years",{"count":63,"type":64},10000,"ESTIMATED","OBSERVATIONAL","This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.",[68,69],"Hematologic Neoplasms","Solid Neoplasm","2026-04-07",{"date":72,"type":73},"2026-04-13","ACTUAL",{"date":75,"type":73},"2016-03-30",{"date":77,"type":64},"2029-03",{"name":5,"class":6},1]